Since graduating from The EpiCentre in March 2022, Amphista has established itself at Granta Park, Cambridge, a world-leading hub for biopharmaceutical innovation. Amphista’s mission is to unlock the full potential of Targeted Protein Degradation (TPD) by developing a new generation of transformational medicines using their proprietary Targeted Glue® technology.
In October 2025, Amphista announced the nomination of AMX-883, a potent, selective, and orally bioavailable degrader of BRD9, as its first clinical development candidate. This breakthrough marks a significant step forward in the treatment of acute myeloid leukaemia (AML), demonstrating Amphista’s commitment to addressing high unmet medical needs with innovative science. The company’s pioneering approach was further highlighted in September 2025, with the identification of SMARCA2 Targeted Glues™, which induce protein degradation via a novel mechanism and enable the development of smaller, more drug-like molecules than conventional PROTAC binders.
Amphista’s growth is powered by a multidisciplinary team of experts, and in April 2025, the company expanded its staff to accelerate its mission and impact. Their journey is a testament to the power of expert support, collaboration, and the dynamic energy fostered at The EpiCentre.
To find out more about Office Space | The EpiCentre | Haverhill, Cambridge (epicentrehaverhill.co.uk)
To find out more about Lab Space | The EpiCentre | Haverhill, Cambridge (epicentrehaverhill.co.uk)
To find out more about Our Members | The EpiCentre | Haverhill, Cambridge (epicentrehaverhill.co.uk)
To find out more about Business Support | EpiCentre | Cambridge, Haverhill (epicentrehaverhill.co.uk)